These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30465867)

  • 1. Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.
    Yamada T; Kashiwagi Y; Rokugawa T; Kato H; Konishi H; Hamada T; Nagai R; Masago Y; Itoh M; Suganami T; Ogawa Y; Abe K
    Magn Reson Imaging; 2019 Apr; 57():210-217. PubMed ID: 30465867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice.
    Yamada T; Obata A; Kashiwagi Y; Rokugawa T; Matsushima S; Hamada T; Watabe H; Abe K
    Magn Reson Imaging; 2016 Jul; 34(6):724-729. PubMed ID: 26979540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging.
    Tsuda N; Okada M; Murakami T
    Invest Radiol; 2007 Apr; 42(4):242-7. PubMed ID: 17351431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of histologic, imaging, and artificial intelligence features in NAFLD patients, derived from Gd-EOB-DTPA-enhanced MRI: a proof-of-concept study.
    Bastati N; Perkonigg M; Sobotka D; Poetter-Lang S; Fragner R; Beer A; Messner A; Watzenboeck M; Pochepnia S; Kittinger J; Herold A; Kristic A; Hodge JC; Traussnig S; Trauner M; Ba-Ssalamah A; Langs G
    Eur Radiol; 2023 Nov; 33(11):7729-7743. PubMed ID: 37358613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The natural history of streptozotocin-stimulated non-alcoholic steatohepatitis mice followed by Gd-EOB-DTPA-enhanced MRI: Comparison with simple steatosis mice.
    Akai H; Kiryu S; Ohta Y; Yasaka K; Nakano Y; Inoue Y; Ohtomo K
    Magn Reson Imaging; 2017 May; 38():123-128. PubMed ID: 28062263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI.
    Tsuda N; Okada M; Murakami T
    Eur J Radiol; 2010 Jan; 73(1):137-42. PubMed ID: 19026502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gd-EOB-DTPA-enhanced T1ρ imaging vs diffusion metrics for assessment liver inflammation and early stage fibrosis of nonalcoholic steatohepatitis in rabbits.
    Xie Y; Zhang H; Jin C; Wang X; Wang X; Chen J; Xu Y
    Magn Reson Imaging; 2018 May; 48():34-41. PubMed ID: 29278765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of Gd-EOB-DTPA-enhanced MR imaging in the evaluation of simple steatosis and nonalcoholic steatohepatitis.
    Wu Z; Matsui O; Kitao A; Kozaka K; Koda W; Kobayashi S; Ryu Y; Minami T; Sanada J; Gabata T
    J Magn Reson Imaging; 2013 May; 37(5):1137-43. PubMed ID: 23172731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice.
    Konuma K; Itoh M; Suganami T; Kanai S; Nakagawa N; Sakai T; Kawano H; Hara M; Kojima S; Izumi Y; Ogawa Y
    PLoS One; 2015; 10(3):e0121528. PubMed ID: 25816330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis.
    Itoh M; Suganami T; Nakagawa N; Tanaka M; Yamamoto Y; Kamei Y; Terai S; Sakaida I; Ogawa Y
    Am J Pathol; 2011 Nov; 179(5):2454-63. PubMed ID: 21906580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple and inexpensive system for controlling body temperature in small animal experiments using MRI and the effect of body temperature on the hepatic kinetics of Gd-EOB-DTPA.
    Murase K; Assanai P; Takata H; Saito S; Nishiura M
    Magn Reson Imaging; 2013 Dec; 31(10):1744-51. PubMed ID: 24094686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.
    Waghorn PA; Ferreira DS; Erstad DJ; Rotile NJ; Masia R; Jones CM; Tu C; Sojoodi M; Chen YI; Schlerman F; Wellen J; Martinez RVP; Tanabe KK; Fuchs BC; Caravan P
    Sci Rep; 2021 Mar; 11(1):6105. PubMed ID: 33731798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic contrast-enhanced MRI of the liver in Mrp2-deficient rats using the hepatobiliary contrast agent Gd-EOB-DTPA.
    Saito S; Obata A; Kashiwagi Y; Abe K; Murase K
    Invest Radiol; 2013 Jul; 48(7):548-53. PubMed ID: 23442774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular MR Imaging of Myeloperoxidase Distinguishes Steatosis from Steatohepatitis in Nonalcoholic Fatty Liver Disease.
    Pulli B; Wojtkiewicz G; Iwamoto Y; Ali M; Zeller MW; Bure L; Wang C; Choi Y; Masia R; Guimaraes AR; Corey KE; Chen JW
    Radiology; 2017 Aug; 284(2):390-400. PubMed ID: 28358240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unenhanced fat fraction ratios obtained by MR and enhanced T2* values with liver-specific MR contrast agents for diagnosis of non-alcoholic steatohepatitis in rats.
    Okada M; Katsube T; Kumano S; Kagawa Y; Araki T; Tsuda N; Okuaki T; Imaoka I; Tanigawa N; Ishii K; Murakami T
    Acta Radiol; 2011 Jul; 52(6):658-64. PubMed ID: 21498305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
    Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis.
    Bae CR; Hino J; Hosoda H; Miyazato M; Kangawa K
    Life Sci; 2018 Sep; 209():349-356. PubMed ID: 30114411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease.
    Ding Y; Rao SX; Meng T; Chen C; Li R; Zeng MS
    Eur Radiol; 2014 Apr; 24(4):959-66. PubMed ID: 24463697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-contrast T1ρ dispersion versus Gd-EOB-DTPA-enhanced T1mapping for the risk stratification of non-alcoholic fatty liver disease in rabbit models.
    Yang R; Chen Z; Pan J; Yang S; Hu F
    Magn Reson Imaging; 2024 Apr; 107():130-137. PubMed ID: 38278311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
    Shiba K; Tsuchiya K; Komiya C; Miyachi Y; Mori K; Shimazu N; Yamaguchi S; Ogasawara N; Katoh M; Itoh M; Suganami T; Ogawa Y
    Sci Rep; 2018 Feb; 8(1):2362. PubMed ID: 29402900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.